Natural killer (NK) cell therapy is an advancing frontier in cellular immunotherapy, with success rates varying extensively across specific clinical trials, target indications, and patient populations. Early-stage trials focusing on refractory autoimmune diseases and oncology have shown promising biomarker responses and depletion metrics, but long-term curative rates continue to be evaluated through ongoing clinical milestones.